Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Premier ethics

This article was originally published in The Gray Sheet

Executive Summary

Board agrees to implement 1recommendations of ethicist Kirk Hansen, Markkula Center for Applied Ethics, Santa Clara University, to address allegations of unfair business practices, the GPO announces Oct. 23. "Best practices" identified in Hansen's report include limiting administrative fees and bundling unrelated products. Premier notes that many of Hansen's recommendations are already being followed (2"The Gray Sheet" Aug. 12, 2002, p. 10)...

You may also be interested in...



Novation, Premier Ban “Up-Front” Administrative Fees In GPO Codes

Novation and Premier are implementing their own GPO operating principles to help assuage Senate Judiciary/Antitrust Subcommittee concerns with the Health Industry Group Purchasing Association's code of conduct

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel